The only US Food and Drug Administration (FDA) approved drug for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis is a thyroid hormone receptor beta (TR-β) agonist [6]. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.